Search Results for "action"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for action. Results 1 to 10 of 338 total matches.
In Brief: Alternatives to Adderall
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022 (Issue 1664)
a stimulant
formulation include onset and duration of action, ease
of administration, and cost. Long-acting ...
The short-acting formulation of mixed amphetamine
salts (Adderall, and generics) FDA-approved for
treatment of attention-deficit hyperactivity disorder
(ADHD) and narcolepsy, is currently in short supply in
the US. Until an adequate supply is restored, patients
may be looking for alternatives.
Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023 (Issue 1667)
of
Action
Duration of
Action Formulations Usual Adult Dose1,2 Cost3 Some Adverse Effects Comments ...
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e6-10 doi:10.58347/tml.2023.1667b | Show Introduction Hide Introduction
Eroxon — An OTC Gel for Erectile Dysfunction
The Medical Letter on Drugs and Therapeutics • Nov 11, 2024 (Issue 1715)
for treatment of ED. The onset of
action is about 30-45 minutes for each of these drugs.
PDE5 inhibitors can ...
The FDA has authorized over-the-counter (OTC)
sale of a nonmedicated alcohol-based gel (Eroxon –
Futura) for treatment of erectile dysfunction (ED) in
males ≥22 years old. Eroxon is the only FDA-approved
OTC and topical treatment for erectile dysfunction. It
is also available in the UK and the EU.
Med Lett Drugs Ther. 2024 Nov 11;66(1715):181-2 doi:10.58347/tml.2024.1715c | Show Introduction Hide Introduction
Addendum: Dexlansoprazole for GERD
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
within 1-2 hours and a second, higher peak within
4-5 hours) and a longer duration of action compared ...
A reader commented that our recent article on
Drugs for GERD and Peptic Ulcer Disease did not
include enough information on dexlansoprazole
(Dexilant, and generics), a proton pump inhibitor
(PPI) claimed to provide "all-day and all-night relief
from heartburn". Dexlansoprazole recently became
available generically, but it is much more expensive
than other generic PPIs.
Drugs for ADHD
The Medical Letter on Drugs and Therapeutics • Sep 01, 2025 (Issue 1736)
in the morning or to
prolong the duration of action in the afternoon.
▶ Common adverse effects include ...
Attention-deficit/hyperactivity disorder (ADHD) is a
common chronic neurodevelopmental disorder often
diagnosed in school-age children that frequently
persists into adulthood.Pharmacologic treatment
of ADHD has been associated with reduced risks of
substance abuse, criminal behavior, unintentional
injuries, serious traffic accidents, and all-cause
mortality. Drugs approved by the FDA for treatment
of ADHD are listed in Table 1.
Med Lett Drugs Ther. 2025 Sep 1;67(1736):137-44 doi:10.58347/tml.2025.1736a | Show Introduction Hide Introduction
In Brief: A New Prostate Cancer Indication for Darolutamide (Nubeqa) (online only)
The Medical Letter on Drugs and Therapeutics • Jun 19, 2023 (Issue 1679)
of nonmetastatic castration-resistant
prostate cancer (nmCRPC).1
MECHANISM OF ACTION — Androgen receptors ...
The androgen receptor inhibitor darolutamide
(Nubeqa – Bayer) has been approved by the FDA
for use in combination with docetaxel for treatment
of metastatic hormone-sensitive prostate cancer
(mHSPC). The drug was previously approved for
treatment of nonmetastatic castration-resistant
prostate cancer (nmCRPC).
Med Lett Drugs Ther. 2023 Jun 19;65(1679):e108 doi:10.58347/tml.2023.1679h | Show Introduction Hide Introduction
Sublingual Cyclobenzaprine (Tonmya) for Fibromyalgia
The Medical Letter on Drugs and Therapeutics • Jan 19, 2026 (Issue 1746)
similar to TCAs. Its mechanism of action for treatment
of fibromyalgia is unclear. Sublingual ...
The FDA has approved Tonmya (Tonix), a sublingual
tablet formulation of the skeletal muscle relaxant
cyclobenzaprine, for treatment of fibromyalgia in
adults. Cyclobenzaprine is available in immediate-release
tablets and extended-release capsules for
short-term treatment of muscle spasms and has been
used off-label for treatment of fibromyalgia.
Med Lett Drugs Ther. 2026 Jan 19;68(1746):9-10 doi:10.58347/tml.2026.1746a | Show Introduction Hide Introduction
Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025 (Issue 1725)
have a rapid onset of action
▶ Efficacy is equal or superior to
that of oral H1-antihistamines
Adverse ...
View the Comparison Table: Some Nasal Sprays for Seasonal Allergic Rhinitis
Med Lett Drugs Ther. 2025 Mar 31;67(1725):e58-63 doi:10.58347/tml.2025.1725c | Show Introduction Hide Introduction
Apoaequorin (Prevagen) to Improve Memory
The Medical Letter on Drugs and Therapeutics • Nov 01, 2021 (Issue 1636)
ACTIONS — In the 2012 FDA letter, the agency
warned the manufacturer of Prevagen about making
false ...
A synthetic form of the protein apoaequorin is the
active ingredient in the over-the-counter dietary
supplement Prevagen (Quincy Bioscience), which
is heavily marketed to improve memory.
Remestemcel-L (Ryoncil) for Graft-Versus-Host Disease (online only)
The Medical Letter on Drugs and Therapeutics • Feb 17, 2025 (Issue 1722)
response in
70% of patients with steroid-refractory acute GVHD.
MECHANISM OF ACTION — In GVHD ...
Remestemcel-L (Ryoncil – Mesoblast), an allogeneic
bone marrow-derived mesenchymal stromal cell
therapy, has been approved by the FDA for treatment
of steroid-refractory acute graft-versus-host disease
(GVHD) in patients ≥2 months old. Steroid-refractory
GVHD is associated with a poor prognosis, organ
damage, and death, particularly in pediatric patients.
Remestemcel-L is the first cellular therapy to be
approved in the US for this indication and the only
treatment of any kind to be approved for GVHD in
children <12 years old.
Med Lett Drugs Ther. 2025 Feb 17;67(1722):e36-7 doi:10.58347/tml.2025.1722i | Show Introduction Hide Introduction
